Skip to content
Studies have shown that active fund managers routinely underperform the S&P500 index*
Home
Articles
WALL STREET X
Forecasts
Portfolios
Wall Street X
Articles
Forecasts
Portfolios
Search
Results for
{phrase}
(
{results_count}
of
{results_count_total}
)
Displaying
{results_count}
results of
{results_count_total}
Virax Biolabs Group Limited (NASDAQ: VRAX)
VRAX Stock Predictions and Ratings
WSX Rating:
STRONG SELL
WSX Forecast (1yr):
-82.60%
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
108.20%
VRAX Stock Analysis
VRAX
PE Ratio:
VRAX
PEG Ratio:
Not Available
VRAX
Forward EPS Growth (12 month):
0.00%
VRAX
PS Ratio:
349.1
VRAX
PSG Ratio:
-5
VRAX
Forward Revenue Growth (12 month):
-70.40%
VRAX Articles
No data was found